Franke A. Quee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Franke A. Quee has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Katja van Den Hurk
Donor Health, Department of Research Sanquin Blood Supply Foundation Amsterdam The Netherlands
12 shared publications - Femmeke J. Prinsze
Donor Health, Department of Research Sanquin Blood Supply Foundation Amsterdam The Netherlands
6 shared publications - Hans L. Zaaijer
Department of Blood-Borne Infections, Donor Medicine Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
5 shared publications Katja van Den Hurk
Department of Public and Occupational Health and the Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands
5 shared publications- Steven Ramondt
Donor Studies, Department of Donor Medicine Research Sanquin Research Amsterdam The Netherlands
5 shared publications - Jan H. M. Karregat
Donor Studies, Department of Donor Medicine Research Sanquin Research Amsterdam The Netherlands
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (43) , 2600103
Trends in hepatitis E virus incidence and seroprevalence in the Netherlands, 1988 to 2025
BACKGROUND: Hepatitis E virus (HEV) can cause serious liver disease, especially in immunosuppressed patients. In 2013, the Netherlands started HEV-RNA screening of donations for production of solvent detergent (S/D)-treated plasma. Since 2017, all Dutch blood donations are screened. AIM: To study trends in HEV infection, we analysed the prevalence of HEV antibodies in Dutch donors since 1988, and HEV-RNA screening results since 2013. METHODS: Prevalence of anti-HEV IgG antibodies was determined in donor samples from 2023, and compared to our previous serosurveillance studies, performed on donor samples collected in 1988, 2000 and 2011. We collected HEV-RNA screening results of S/D plasma donations since 2013, and of all blood donations since 2017. RESULTS: In 2023, 24.3% of donors tested positive for anti-HEV antibodies. Seroprevalence increased with age. An age-cohort effect contributed to an overall decline in seroprevalence compared with 1988, reflecting historically higher infection pressure. Among donors born after 1950, seroprevalence rose in samples collected after 2000. HEV-RNA screening results initially revealed a high incidence that declined sharply after 2015, followed by an upward trend beginning in 2020. HEV-RNA positivity was more common in male and older donors. CONCLUSION: The data indicate substantial historical fluctuations of HEV infection pressure. High seroprevalence in the late 20th century suggests widespread past exposure, followed by a prolonged period of reduced infection rates. Around 2000, HEV appears to have re-emerged, with increasing seroprevalence among younger donors. Screening has revealed marked year-to-year variability in incidence, underscoring dynamic patterns of HEV circulation.
- 29 October 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (43) , 2600103
Open AccessTrends in hepatitis E virus incidence and seroprevalence in the Netherlands, 1988 to 2025
BACKGROUND: Hepatitis E virus (HEV) can cause serious liver disease, especially in immunosuppressed patients. In 2013, the Netherlands started HEV-RNA screening of donations for production of solvent detergent (S/D)-treated plasma. Since 2017, all Dutch blood donations are screened. AIM: To study trends in HEV infection, we analysed the prevalence of HEV antibodies in Dutch donors since 1988, and HEV-RNA screening results since 2013. METHODS: Prevalence of anti-HEV IgG antibodies was determined in donor samples from 2023, and compared to our previous serosurveillance studies, performed on donor samples collected in 1988, 2000 and 2011. We collected HEV-RNA screening results of S/D plasma donations since 2013, and of all blood donations since 2017. RESULTS: In 2023, 24.3% of donors tested positive for anti-HEV antibodies. Seroprevalence increased with age. An age-cohort effect contributed to an overall decline in seroprevalence compared with 1988, reflecting historically higher infection pressure. Among donors born after 1950, seroprevalence rose in samples collected after 2000. HEV-RNA screening results initially revealed a high incidence that declined sharply after 2015, followed by an upward trend beginning in 2020. HEV-RNA positivity was more common in male and older donors. CONCLUSION: The data indicate substantial historical fluctuations of HEV infection pressure. High seroprevalence in the late 20th century suggests widespread past exposure, followed by a prolonged period of reduced infection rates. Around 2000, HEV appears to have re-emerged, with increasing seroprevalence among younger donors. Screening has revealed marked year-to-year variability in incidence, underscoring dynamic patterns of HEV circulation.
- 3 August 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (10) , 1034-1037
SARS‐CoV‐2 infection after August 2022 in Dutch blood donors without serological signs of prior infection
Background and Objectives: After several years of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) circulation in the Netherlands, most individuals acquired the infection. However, an unknown number of uninfected persons could still be solely dependent on vaccination for protection. In this study, we aimed to retrospectively quantify the proportion of blood donors, without signs of prior SARS‐CoV‐2 infection, who acquired SARS‐CoV‐2 infection after August 2022.Materials and Methods: Based on data collected in previous SARS‐CoV‐2 serosurveillance studies, we created a cohort of donors who tested negative for anti‐nucleocapsid (NC) antibodies between August 2022 and September 2023. If these donors donated blood during the follow‐up period, between 1 October 2023 and 12 September 2024, their donation was again tested for anti‐NC to see whether they seroconverted.Results: Of the 992 donors whose donation(s) tested negative for anti‐NC between August 2022 and September 2023, 824 (83%) donated during the follow‐up period. Older donors were overrepresented in the study. Of the included donors, 67% seroconverted for anti‐NC after August 2022.Conclusion: The majority of Dutch blood donors who were still uninfected acquired primary infection after August 2022, coinciding with the circulation of SARS‐CoV‐2 omicron variants.
- 3 August 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (10) , 1034-1037
SARS‐CoV‐2 infection after August 2022 in Dutch blood donors without serological signs of prior infection
Background and Objectives: After several years of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) circulation in the Netherlands, most individuals acquired the infection. However, an unknown number of uninfected persons could still be solely dependent on vaccination for protection. In this study, we aimed to retrospectively quantify the proportion of blood donors, without signs of prior SARS‐CoV‐2 infection, who acquired SARS‐CoV‐2 infection after August 2022.Materials and Methods: Based on data collected in previous SARS‐CoV‐2 serosurveillance studies, we created a cohort of donors who tested negative for anti‐nucleocapsid (NC) antibodies between August 2022 and September 2023. If these donors donated blood during the follow‐up period, between 1 October 2023 and 12 September 2024, their donation was again tested for anti‐NC to see whether they seroconverted.Results: Of the 992 donors whose donation(s) tested negative for anti‐NC between August 2022 and September 2023, 824 (83%) donated during the follow‐up period. Older donors were overrepresented in the study. Of the included donors, 67% seroconverted for anti‐NC after August 2022.Conclusion: The majority of Dutch blood donors who were still uninfected acquired primary infection after August 2022, coinciding with the circulation of SARS‐CoV‐2 omicron variants.
- Open Access
Ferritin-guided iron supplementation in whole blood donors (FORTE): results of a double-blind randomized controlled trial
BACKGROUND Regular blood donation is associated with an increased risk of iron deficiency (ID; ferritin METHODS In this prospective randomized placebo-controlled trial donors with ferritin levels ≤30 µg/L were enrolled in the study and randomly assigned to one of six groups, stratified for sex and age. Depending on the study arm, donors were asked to adhere to a ferrous bisglycinate supplementation protocol for 56 days, taking capsules containing 0 mg (i.e. placebo), 30 mg or 60 mg of elemental iron, either on alternate days or daily. The primary outcome was iron deficiency (ID) at 56 days follow-up, while secondary outcomes included low ferritin (≤30 µg/L), low Hb (≤135 g/L for men and ≤125 g/L for women), iron deficiency-related symptoms, side effects, treatment adherence, and evaluations of all outcomes at 122 and 180 days follow-up. This trial is registered in the Dutch trial registry (NL73283.018.20). FINDINGS Of the 2,052 donors who provided their informed consent, 830 donors (464 women) had ferritin levels ≤30 µg/L and were included in the trial. Compared to placebo, all iron supplementation groups exhibited similar significantly lower odds of ID at 56 days, with odds ratios (OR) ranging from 0.60 (95% CI [0.55–0.66]) to 0.65 (95% CI [0.59–0.72]). Similarly, for low Hb, the OR’s ranged from 0.74 (95% CI [0.64–0.86]) to 0.80 (95% CI [0.68–0.93]) For low ferritin, 60 mg of daily iron supplementation yielded an OR of 0.52 (95% CI [0.47–0.57]), markedly lower than those of other protocols, which ranged from 0.61 (95% CI [0.55–0.68]) to 0.82 (95% CI [0.74–0.91]). Iron supplementation did not result in any significant differences compared to placebo in ID-related symptoms, gastrointestinal side effects, intention to return to donate, or treatment adherence. INTERPRETATION In regular donors, 60 mg iron supplements taken daily was shown to be the most effective strategy for mitigating ID, low Hb, and especially low ferritin without introducing gastrointestinal discomfort or changes in the donors intention to return to donate. Ferritin-guided iron supplementation is an effective iron management strategy as an alternative or supplement to extended donation intervals.
Open AccessFerritin-guided iron supplementation in whole blood donors (FORTE): results of a double-blind randomized controlled trial
BACKGROUND Regular blood donation is associated with an increased risk of iron deficiency (ID; ferritin METHODS In this prospective randomized placebo-controlled trial donors with ferritin levels ≤30 µg/L were enrolled in the study and randomly assigned to one of six groups, stratified for sex and age. Depending on the study arm, donors were asked to adhere to a ferrous bisglycinate supplementation protocol for 56 days, taking capsules containing 0 mg (i.e. placebo), 30 mg or 60 mg of elemental iron, either on alternate days or daily. The primary outcome was iron deficiency (ID) at 56 days follow-up, while secondary outcomes included low ferritin (≤30 µg/L), low Hb (≤135 g/L for men and ≤125 g/L for women), iron deficiency-related symptoms, side effects, treatment adherence, and evaluations of all outcomes at 122 and 180 days follow-up. This trial is registered in the Dutch trial registry (NL73283.018.20). FINDINGS Of the 2,052 donors who provided their informed consent, 830 donors (464 women) had ferritin levels ≤30 µg/L and were included in the trial. Compared to placebo, all iron supplementation groups exhibited similar significantly lower odds of ID at 56 days, with odds ratios (OR) ranging from 0.60 (95% CI [0.55–0.66]) to 0.65 (95% CI [0.59–0.72]). Similarly, for low Hb, the OR’s ranged from 0.74 (95% CI [0.64–0.86]) to 0.80 (95% CI [0.68–0.93]) For low ferritin, 60 mg of daily iron supplementation yielded an OR of 0.52 (95% CI [0.47–0.57]), markedly lower than those of other protocols, which ranged from 0.61 (95% CI [0.55–0.68]) to 0.82 (95% CI [0.74–0.91]). Iron supplementation did not result in any significant differences compared to placebo in ID-related symptoms, gastrointestinal side effects, intention to return to donate, or treatment adherence. INTERPRETATION In regular donors, 60 mg iron supplements taken daily was shown to be the most effective strategy for mitigating ID, low Hb, and especially low ferritin without introducing gastrointestinal discomfort or changes in the donors intention to return to donate. Ferritin-guided iron supplementation is an effective iron management strategy as an alternative or supplement to extended donation intervals.
- Open Access
- 14 August 2024
- Published by Wiley in Transfusion
- Vol. 64 (10) , 1920-1930
Iron deficiency‐related symptoms in non‐anemic whole blood donors
Introduction: Whole blood donors are at increased risk for iron deficiency (ID). ID anemia is associated with several symptoms, such as fatigue, cognitive dysfunction, pica, and restless leg syndrome (RLS). However, it is unclear if these symptoms also occur when a donor has developed ID without anemia. This study aims to determine whether non‐anemic ID (NAID) is associated with the occurrence of ID‐related symptoms.Study Designs and Methods: We combined data from three studies in whole blood donors (i.e., Donor Insight‐III, FIND'EM, and FORTE) to create a substantial sample size (N = 12,143). The self‐reported occurrence and severity of ID‐related symptoms, such as physical and mental health, fatigue, cognitive functioning, pica, and RLS, was measured using validated questionnaires. Associations were studied using logistic regression modeling with ID‐related symptoms derived from the questionnaires as the dependent variable and ferritin level group (0–15 μg/L, 15–30 μg/L, and >30 μg/L) as explanatory variable.Results: After applying inclusion and exclusion criteria, 9829 donors were eligible for analysis. In the models corrected for age, body mass index, Hb level, and cohort, only fatigue was shown to be associated with ferritin levels in men, showing lower odds (OR 1.41, 95% CI 1.11–1.79) for fatigue with higher ferritin levels.Conclusion: In these studies, NAID was only associated with self‐reported fatigue in male donors. Although selection bias may have led to underestimated associations, ferritin measurements in donors should be primarily considered as a measure to prevent anemia, rather than to prevent or mitigate NAID‐related symptoms.
- 14 August 2024
- Published by Wiley in Transfusion
- Vol. 64 (10) , 1920-1930
Open AccessIron deficiency‐related symptoms in non‐anemic whole blood donors
Introduction: Whole blood donors are at increased risk for iron deficiency (ID). ID anemia is associated with several symptoms, such as fatigue, cognitive dysfunction, pica, and restless leg syndrome (RLS). However, it is unclear if these symptoms also occur when a donor has developed ID without anemia. This study aims to determine whether non‐anemic ID (NAID) is associated with the occurrence of ID‐related symptoms.Study Designs and Methods: We combined data from three studies in whole blood donors (i.e., Donor Insight‐III, FIND'EM, and FORTE) to create a substantial sample size (N = 12,143). The self‐reported occurrence and severity of ID‐related symptoms, such as physical and mental health, fatigue, cognitive functioning, pica, and RLS, was measured using validated questionnaires. Associations were studied using logistic regression modeling with ID‐related symptoms derived from the questionnaires as the dependent variable and ferritin level group (0–15 μg/L, 15–30 μg/L, and >30 μg/L) as explanatory variable.Results: After applying inclusion and exclusion criteria, 9829 donors were eligible for analysis. In the models corrected for age, body mass index, Hb level, and cohort, only fatigue was shown to be associated with ferritin levels in men, showing lower odds (OR 1.41, 95% CI 1.11–1.79) for fatigue with higher ferritin levels.Conclusion: In these studies, NAID was only associated with self‐reported fatigue in male donors. Although selection bias may have led to underestimated associations, ferritin measurements in donors should be primarily considered as a measure to prevent anemia, rather than to prevent or mitigate NAID‐related symptoms.
- Open Access
- 18 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0305613
The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance
Introduction: Serological surveillance is useful for assessing SARS-CoV-2 immunity in populations. To effectively study the presence and persistence of antibodies, it is necessary to distinguish between persons with past infection, and persons who only received vaccination. Knowledge of the duration of antibody persistence is essential for correct interpretation of surveillance results. Methods: Starting in April 2020, waning of SARS-CoV-2 antibodies was studied in a longitudinal cohort study of 495 SARS-CoV-2 antibody-positive Dutch blood donors, not pre-selected by PCR testing or disease severity. Additionally, in May 2021, a sample of donors representative for the Dutch population was tested for antibodies against the SARS-CoV-2 spike (S) protein, using the Wantai Ab ELISA and the Elecsys® Anti-SARS-CoV-2 S assay; and for antibodies against the nucleocapsid protein, which indicate past infection, using the Elecsys® Anti-SARS-CoV-2 assay. Results: The anti-S response in donors that were infected in April or May 2020 remained positive in 100% of donors in the Elecsys® Anti-SARS-CoV-2 S assay one year after infection, after which follow up of waning was no longer possible because of large scale vaccination. The anti-nucleocapsid response results were still positive in approximately 80% of donors two years after infection. In May 2021, 51% of the donors showed anti-S reactivity and 16.8% tested positive for anti-nucleocapsid antibodies. Conclusion: Infection with SARS-CoV-2 resulted in spike and nucleocapsid antibody levels still detectable in the majority of donors 1–2 years after infection. In May 2021, 51% of donors were vaccinated and 16.8% had had an infection. Thus, both Elecsys® SARS-CoV-2 antibody assays can be used to reliably assess the vaccination and infection status of individuals.
- 18 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0305613
Open AccessThe Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance
Introduction: Serological surveillance is useful for assessing SARS-CoV-2 immunity in populations. To effectively study the presence and persistence of antibodies, it is necessary to distinguish between persons with past infection, and persons who only received vaccination. Knowledge of the duration of antibody persistence is essential for correct interpretation of surveillance results. Methods: Starting in April 2020, waning of SARS-CoV-2 antibodies was studied in a longitudinal cohort study of 495 SARS-CoV-2 antibody-positive Dutch blood donors, not pre-selected by PCR testing or disease severity. Additionally, in May 2021, a sample of donors representative for the Dutch population was tested for antibodies against the SARS-CoV-2 spike (S) protein, using the Wantai Ab ELISA and the Elecsys® Anti-SARS-CoV-2 S assay; and for antibodies against the nucleocapsid protein, which indicate past infection, using the Elecsys® Anti-SARS-CoV-2 assay. Results: The anti-S response in donors that were infected in April or May 2020 remained positive in 100% of donors in the Elecsys® Anti-SARS-CoV-2 S assay one year after infection, after which follow up of waning was no longer possible because of large scale vaccination. The anti-nucleocapsid response results were still positive in approximately 80% of donors two years after infection. In May 2021, 51% of the donors showed anti-S reactivity and 16.8% tested positive for anti-nucleocapsid antibodies. Conclusion: Infection with SARS-CoV-2 resulted in spike and nucleocapsid antibody levels still detectable in the majority of donors 1–2 years after infection. In May 2021, 51% of donors were vaccinated and 16.8% had had an infection. Thus, both Elecsys® SARS-CoV-2 antibody assays can be used to reliably assess the vaccination and infection status of individuals.
- Open Access
- 10 July 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (10) , 1047-1057
Donor knowledge and perceptions regarding donation‐induced iron depletion and iron supplementation as a blood service policy
Background and Objectives: Regular whole blood donations are associated with an increased risk of iron deficiency. Iron supplementation is an effective strategy to prevent donation‐induced iron deficiency. However, research on donor perceptions towards such a policy is limited. Therefore, we aim to evaluate donors' knowledge on donation‐induced iron depletion and their perceptions regarding iron supplementation as a blood service policy.Materials and Methods: Three thousand Dutch whole blood donors were invited to complete a survey assessing their knowledge of donation‐induced iron depletion and attitudes and perceptions towards iron supplementation as a policy. Linear regression modelling was used to evaluate associations between explanatory variables and perceptions.Results: In total, 1093 (77.1%) donors were included in the analysis. Donors had poor knowledge of current iron management policies, but a better understanding of iron metabolism and supplementation. Iron supplementation as a policy was perceived mainly positive by donors, and the majority were willing to use iron supplements if provided. Iron supplementation was not perceived as invasive or negatively affecting donors' motivation to continue donating. Additional iron monitoring, information and donor physician involvement were regarded as important conditions for implementation. Male sex, trust in the blood service, prior experience with iron supplements and openness towards dietary supplements were strongly positively associated with willingness to use iron supplementation.Conclusion: Donors' knowledge regarding donation‐induced iron depletion is limited, but not associated with their perceptions regarding iron supplementation. Donors do not consider iron supplementation as invasive, deterring or demotivating, and a majority are willing to take supplements if offered.
- 10 July 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (10) , 1047-1057
Open AccessDonor knowledge and perceptions regarding donation‐induced iron depletion and iron supplementation as a blood service policy
Background and Objectives: Regular whole blood donations are associated with an increased risk of iron deficiency. Iron supplementation is an effective strategy to prevent donation‐induced iron deficiency. However, research on donor perceptions towards such a policy is limited. Therefore, we aim to evaluate donors' knowledge on donation‐induced iron depletion and their perceptions regarding iron supplementation as a blood service policy.Materials and Methods: Three thousand Dutch whole blood donors were invited to complete a survey assessing their knowledge of donation‐induced iron depletion and attitudes and perceptions towards iron supplementation as a policy. Linear regression modelling was used to evaluate associations between explanatory variables and perceptions.Results: In total, 1093 (77.1%) donors were included in the analysis. Donors had poor knowledge of current iron management policies, but a better understanding of iron metabolism and supplementation. Iron supplementation as a policy was perceived mainly positive by donors, and the majority were willing to use iron supplements if provided. Iron supplementation was not perceived as invasive or negatively affecting donors' motivation to continue donating. Additional iron monitoring, information and donor physician involvement were regarded as important conditions for implementation. Male sex, trust in the blood service, prior experience with iron supplements and openness towards dietary supplements were strongly positively associated with willingness to use iron supplementation.Conclusion: Donors' knowledge regarding donation‐induced iron depletion is limited, but not associated with their perceptions regarding iron supplementation. Donors do not consider iron supplementation as invasive, deterring or demotivating, and a majority are willing to take supplements if offered.
- 4 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1732-1742
Blood safety markers in Dutch donors after relaxation of deferral for men who have sex with men: re‐emergence of syphilis and HIV pre‐exposure prophylaxis use
Background: Less discriminatory donor selection policies for men who have sex with men (MSM) may impact transfusion safety in terms of higher residual risks for known transfusion‐transmitted infections (TTIs), increased vulnerability toward new TTIs that are also transmitted via sex, and HIV infections masked by pre‐exposure prophylaxis (PrEP).Study Design and Methods: TTI trends in Dutch donors were studied over a 13‐year period (2011–2023), characterized by successive relaxations of MSM deferral criteria. Structured posttest counseling was performed to determine risk factors in TTI‐positive donors. PrEP drug levels were measured in 9977 donations from male donors living in urban areas and in 67 donors with active or resolved syphilis.Results: HIV incidence (from 5.8 to 1.5 per 1,000,000 donor years (DY)) and HBV incidence (from 12.4 to 4.5 per 1,000,000 DY) in Dutch donors decreased with less stringent MSM deferral criteria, while syphilis prevalence (from 26.4 to 44.1 per 100,000 new donors) and syphilis incidence (from 18.3 to 46.3 per 1,000,000 DY) increased over time. The proportion of MSM‐related syphilis rose from 2% to 32% in new donors and from 12% to 27% in repeat donors. PrEP was detected in 2 of 9977 (0.02%) donations from male donors living in urban areas, and in 1 of 39 (2.6%) male donors with syphilis.Discussion: To date, phasing out donor deferral for MSM had no significant impact on transfusion safety in the Netherlands. However, rising syphilis rates and (recent) PrEP use in the blood donor population, albeit rare, suggest an influx of donors with higher sexual risk profiles and requires intensified TTI surveillance in donors.
- 4 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1732-1742
Blood safety markers in Dutch donors after relaxation of deferral for men who have sex with men: re‐emergence of syphilis and HIV pre‐exposure prophylaxis use
Background: Less discriminatory donor selection policies for men who have sex with men (MSM) may impact transfusion safety in terms of higher residual risks for known transfusion‐transmitted infections (TTIs), increased vulnerability toward new TTIs that are also transmitted via sex, and HIV infections masked by pre‐exposure prophylaxis (PrEP).Study Design and Methods: TTI trends in Dutch donors were studied over a 13‐year period (2011–2023), characterized by successive relaxations of MSM deferral criteria. Structured posttest counseling was performed to determine risk factors in TTI‐positive donors. PrEP drug levels were measured in 9977 donations from male donors living in urban areas and in 67 donors with active or resolved syphilis.Results: HIV incidence (from 5.8 to 1.5 per 1,000,000 donor years (DY)) and HBV incidence (from 12.4 to 4.5 per 1,000,000 DY) in Dutch donors decreased with less stringent MSM deferral criteria, while syphilis prevalence (from 26.4 to 44.1 per 100,000 new donors) and syphilis incidence (from 18.3 to 46.3 per 1,000,000 DY) increased over time. The proportion of MSM‐related syphilis rose from 2% to 32% in new donors and from 12% to 27% in repeat donors. PrEP was detected in 2 of 9977 (0.02%) donations from male donors living in urban areas, and in 1 of 39 (2.6%) male donors with syphilis.Discussion: To date, phasing out donor deferral for MSM had no significant impact on transfusion safety in the Netherlands. However, rising syphilis rates and (recent) PrEP use in the blood donor population, albeit rare, suggest an influx of donors with higher sexual risk profiles and requires intensified TTI surveillance in donors.
- Open Access
- 8 April 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (7) , 648-655
Increasing the upper age limit for blood donation: Perspectives from older donors
Background and Objectives: In the Netherlands, as of April 2018, the upper age limit for blood donation has been raised from 69 to 79 years, providing an opportunity to study older donors' perspectives regarding donating at older age. This study aims to explore whether older donors agree with the increase of the age limit, if they feel obliged to continue donating, to identify their motivators and barriers for donating blood and describe donation‐related experiences and complications.Materials and Methods: An online survey was distributed among Dutch blood donors aged 68–73 years. The survey contained questions regarding the increase of the upper age limit, motivations and barriers for donating, donation‐related experiences and obligatory feelings to continue donating.Results: Six hundred sixty donors (55%) were included in the analyses, including 38 stopped donors. Most donors (92%) agreed with the increase of the upper age limit. Approximately 63% of participating donors felt obliged to continue donating, especially women with high education. Donors indicated they felt healthy enough to keep donating (95%), and 72% thought it is good for their health to keep donating. Few donors reported that they found it hard to keep donating (5%) or indicated that they did not feel healthy enough to donate or thought it was not safe for them anymore (3.4%).Conclusion: Most of the older donors agree with the increase of the upper age limit for blood donation, report only few and minor donation‐related experiences or complications and are highly motivated to continue their donor career at an older age.
- 8 April 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (7) , 648-655
Open AccessIncreasing the upper age limit for blood donation: Perspectives from older donors
Background and Objectives: In the Netherlands, as of April 2018, the upper age limit for blood donation has been raised from 69 to 79 years, providing an opportunity to study older donors' perspectives regarding donating at older age. This study aims to explore whether older donors agree with the increase of the age limit, if they feel obliged to continue donating, to identify their motivators and barriers for donating blood and describe donation‐related experiences and complications.Materials and Methods: An online survey was distributed among Dutch blood donors aged 68–73 years. The survey contained questions regarding the increase of the upper age limit, motivations and barriers for donating, donation‐related experiences and obligatory feelings to continue donating.Results: Six hundred sixty donors (55%) were included in the analyses, including 38 stopped donors. Most donors (92%) agreed with the increase of the upper age limit. Approximately 63% of participating donors felt obliged to continue donating, especially women with high education. Donors indicated they felt healthy enough to keep donating (95%), and 72% thought it is good for their health to keep donating. Few donors reported that they found it hard to keep donating (5%) or indicated that they did not feel healthy enough to donate or thought it was not safe for them anymore (3.4%).Conclusion: Most of the older donors agree with the increase of the upper age limit for blood donation, report only few and minor donation‐related experiences or complications and are highly motivated to continue their donor career at an older age.
- Open Access
- 20 October 2023
- Published by Wiley in Vox Sanguinis
- Vol. 119 (1) , 16-26
Iron supplementation: A qualitative study on the perception of blood donors, blood collection staff and donor physicians
Background and Objectives: Iron supplementation is an effective strategy to mitigate donation‐induced iron deficiency in blood donors. However, evidence on the perception of individuals involved in blood donation on iron supplementation as a blood service policy is lacking. This study aimed to evaluate the knowledge and perception of whole blood donors (donors), blood collection staff (collection staff) and donor physicians (physicians) regarding donation‐induced iron loss and iron supplementation.Materials and Methods: Online focus group discussions had four to six participants and followed a structured questioning approach. All participants had to be fluent in Dutch to participate, and donors had donated at least five times. Sixteen donors, eight collection staff members and four physicians participated in this study. Recordings were transcribed, coded and analysed using a grounded theory approach.Results: Awareness of donation‐induced iron loss was limited in donors. Donors and physicians were predominantly positive towards iron supplementation; the primary motivator for donors was to prevent deferral and reduce iron‐deficiency‐related symptoms. Improving donor health was the main argument for physicians to advocate iron supplementation. Staff had a critical view on iron supplementation as a policy, as they perceived it as unethical and possibly ineffective. A knowledge gap might underlie their concerns.Conclusion: Most individuals involved in blood donation are positive towards iron supplementation as a blood service policy. If implemented, guidance and monitoring is desired and adequate education of all stakeholders is required.
- 20 October 2023
- Published by Wiley in Vox Sanguinis
- Vol. 119 (1) , 16-26
Open AccessIron supplementation: A qualitative study on the perception of blood donors, blood collection staff and donor physicians
Background and Objectives: Iron supplementation is an effective strategy to mitigate donation‐induced iron deficiency in blood donors. However, evidence on the perception of individuals involved in blood donation on iron supplementation as a blood service policy is lacking. This study aimed to evaluate the knowledge and perception of whole blood donors (donors), blood collection staff (collection staff) and donor physicians (physicians) regarding donation‐induced iron loss and iron supplementation.Materials and Methods: Online focus group discussions had four to six participants and followed a structured questioning approach. All participants had to be fluent in Dutch to participate, and donors had donated at least five times. Sixteen donors, eight collection staff members and four physicians participated in this study. Recordings were transcribed, coded and analysed using a grounded theory approach.Results: Awareness of donation‐induced iron loss was limited in donors. Donors and physicians were predominantly positive towards iron supplementation; the primary motivator for donors was to prevent deferral and reduce iron‐deficiency‐related symptoms. Improving donor health was the main argument for physicians to advocate iron supplementation. Staff had a critical view on iron supplementation as a policy, as they perceived it as unethical and possibly ineffective. A knowledge gap might underlie their concerns.Conclusion: Most individuals involved in blood donation are positive towards iron supplementation as a blood service policy. If implemented, guidance and monitoring is desired and adequate education of all stakeholders is required.
- Open Access
Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: Results of the Stepped-wedge Cluster Randomised FIND’EM Trial
Background: Whole blood donors are at increased risk for iron deficiency and anaemia. The current standard of haemoglobin (Hb) monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. We determine the effects of ferritin-guided donation intervals for blood donors and the blood supply. Methods: A ferritin-guided donation interval policy was implemented and evaluated through a stepped-wedge cluster-randomised controlled trial in all blood collection centres in the Netherlands. Ferritin was measured in new donors and at every 5th donation. Subsequent donation intervals were extended to six months if ferritin was 15 - 30 ng/mL and to twelve months if ferritin was th , 2017 ( https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738 ).
Open AccessEffectiveness of Ferritin-guided Donation Intervals in Blood Donors: Results of the Stepped-wedge Cluster Randomised FIND’EM Trial
Background: Whole blood donors are at increased risk for iron deficiency and anaemia. The current standard of haemoglobin (Hb) monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. We determine the effects of ferritin-guided donation intervals for blood donors and the blood supply. Methods: A ferritin-guided donation interval policy was implemented and evaluated through a stepped-wedge cluster-randomised controlled trial in all blood collection centres in the Netherlands. Ferritin was measured in new donors and at every 5th donation. Subsequent donation intervals were extended to six months if ferritin was 15 - 30 ng/mL and to twelve months if ferritin was th , 2017 ( https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738 ).